Secukinumab: A Silver Lining in Dermatology

IF 0.4 Q4 PHARMACOLOGY & PHARMACY

Journal of Pharmacology & Pharmacotherapeutics Pub Date : 2022-06-01 DOI:10.1177/0976500X221105921

D. Manoharan, Ravi Vignesh N., Srinivasan Shreya, Saravanan Suzsmi L.

{"title":"Secukinumab: A Silver Lining in Dermatology","authors":"D. Manoharan, Ravi Vignesh N., Srinivasan Shreya, Saravanan Suzsmi L.","doi":"10.1177/0976500X221105921","DOIUrl":null,"url":null,"abstract":"Secukinumab, a fully human monoclonal antibody, is a biological agent that targets interleukin-17A. Secukinumab is used in the management of the common dermatological entity - plaque-type psoriasis and its various types, namely psoriatic arthritis, hypertrophic palmoplantar psoriasis and generalized pustular psoriasis. Other less common indications of this popular interleukin -17A inhibitor, secukinumab include ankylosing spondylitis, rheumatoid arthritis, systemic lupus erythematosus, Familial Mediterranean fever, and tumor necrosis factor receptor-associated periodic syndrome (TRAPS). This review article was written by referring to various review articles, original articles, and some books related to highly regarded databases, such as the Web of Science, PubMed, and Scopus. The keywords explored during review of literature consisted of combinations of the following words: human monoclonal antibody, IL-17A, and biologicals. The authors with this in-depth review hope to explore the working of this versatile biological, Secukinumab, especially as a silver lining in dermatology.","PeriodicalId":16761,"journal":{"name":"Journal of Pharmacology & Pharmacotherapeutics","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacology & Pharmacotherapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/0976500X221105921","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Secukinumab, a fully human monoclonal antibody, is a biological agent that targets interleukin-17A. Secukinumab is used in the management of the common dermatological entity - plaque-type psoriasis and its various types, namely psoriatic arthritis, hypertrophic palmoplantar psoriasis and generalized pustular psoriasis. Other less common indications of this popular interleukin -17A inhibitor, secukinumab include ankylosing spondylitis, rheumatoid arthritis, systemic lupus erythematosus, Familial Mediterranean fever, and tumor necrosis factor receptor-associated periodic syndrome (TRAPS). This review article was written by referring to various review articles, original articles, and some books related to highly regarded databases, such as the Web of Science, PubMed, and Scopus. The keywords explored during review of literature consisted of combinations of the following words: human monoclonal antibody, IL-17A, and biologicals. The authors with this in-depth review hope to explore the working of this versatile biological, Secukinumab, especially as a silver lining in dermatology.

查看原文本刊更多论文

Secukinumab：皮肤病学的一线希望

Secukinumab是一种全人源单克隆抗体，是一种靶向白介素- 17a的生物制剂。Secukinumab用于治疗常见的皮肤病——斑块型银屑病及其各种类型，即银屑病关节炎、肥厚性掌跖型银屑病和全身性脓疱性银屑病。这种流行的白细胞介素-17A抑制剂secukinumab的其他不太常见的适应症包括强直性脊柱炎、类风湿性关节炎、系统性红斑狼疮、家族性地中海热和肿瘤坏死因子受体相关周期性综合征(TRAPS)。这篇评论文章是通过参考各种评论文章、原创文章和一些与高度重视的数据库(如Web of Science、PubMed和Scopus)相关的书籍而撰写的。在查阅文献的过程中，检索到的关键词由以下词语组合而成:人单克隆抗体、IL-17A、生物制剂。这篇深入的综述的作者希望探索这种多功能生物学，Secukinumab的工作，特别是作为皮肤病学的一线希望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Pharmacology & Pharmacotherapeutics PHARMACOLOGY & PHARMACY-

CiteScore

0.40

自引率

0.00%

发文量